Goldman Sachs lowers Alnylam price target to $320 from $536
Goldman Sachs cut its price target on Alnylam Pharmaceuticals shares to $320 from $536, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that Goldman Sachs has revised its price target on Alnylam Pharmaceuticals shares, reducing it to $320 from $536. This is an analyst rating decision from the bank, not new information about the company's financial condition.
The revision reflects one bank's view of the stock's future value and typically affects only sentiment around the shares.
why it matters
Price target changes are a routine event for the market. For Alnylam shares, the company's earnings and the broader biotech sector trend matter more.
tags
instruments
sources
- Alnylam Pharmaceuticals Price Target Cut to $320.00/Share From $536.00 by Goldman Sachs — Dow Jones Newswires, 30 October 2026 at 17:35 UTC
- Coinbase Price Target Cut to $210.00/Share From $244.00 by Goldman Sachs — Dow Jones Newswires, 30 October 2026 at 17:43 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗